Feedback

Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies

Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Cheng, Fang;
Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Zhang, Ruoqi;
Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Sun, Chen;
Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Ran, Qian;
Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Zhang, Cuihan;
Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Shen, Changhong;
Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Yao, Ziqing;
Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Wang, Miao;
Affiliation
Department of Pharmacy, Children’s Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics ,Chongqing ,China
Song, Lin;
Affiliation
State Key Laboratory of Southwestern Chinese Medicine Resources ,Chengdu University of Traditional Chinese Medicine ,Chengdu ,China
Peng, Cheng

Oxaliplatin-based chemotherapy is a standard treatment approach for colorectal cancer (CRC). However, oxaliplatin-induced peripheral neurotoxicity (OIPN) is a severe dose-limiting clinical problem that might lead to treatment interruption. This neuropathy may be reversible after treatment discontinuation. Its complicated mechanisms are related to DNA damage, dysfunction of voltage-gated ion channels, neuroinflammation, transporters, oxidative stress, and mitochondrial dysfunction, etc. Several strategies have been proposed to diminish OIPN without compromising the efficacy of adjuvant therapy, namely, combination with chemoprotectants (such as glutathione, Ca/Mg, ibudilast, duloxetine, etc. ), chronomodulated infusion, dose reduction, reintroduction of oxaliplatin and topical administration [hepatic arterial infusion chemotherapy (HAIC), pressurized intraperitoneal aerosol chemotherapy (PIPAC), and hyperthermic intraperitoneal chemotherapy (HIPEC)]. This article provides recent updates related to the potential mechanisms, therapeutic strategies in treatment of OIPN, and pharmacokinetics of several methods of oxaliplatin administration in clinical trials.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Cheng, Zhang, Sun, Ran, Zhang, Shen, Yao, Wang, Song and Peng.

Use and reproduction: